Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...
pharmaphorum1d
Sanofi wins appeal in spat with NICE over Sarclisa
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
pharmaphorum4d
J&J bids to add smouldering myeloma to Darzalex label
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
The Pharma Letter2d
UK looks again at Sarclisa for myeloma as demand grows
Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...
National Institute for Health and Care Excellence2d
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]
27 September 2023 This appraisal is expected to start during early October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an ...
Indiatimes3d
Sanofi India Share Price
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...